99.6% PURITY LOT VL-2930-A TB-500
A synthetic thymosin β4-derived peptide supplied as a 5 mg lyophilized vial for research into actin binding and sequestration, cell migration, angiogenesis, and tissue repair.
A synthetic thymosin β4-derived peptide supplied as a 10 mg lyophilized vial for research into actin binding and sequestration, cell migration, angiogenesis, and tissue repair.
- 1 × TB-500 5mg vial
- Tamper-evident flip-off cap
- Batch-tested for purity (≥99%)
- Lyophilized for stability during shipping
- Bacteriostatic water (3 mL)
- 1 × TB-500 10mg vial
- Tamper-evident flip-off cap
- Batch-tested for purity (≥99%)
- Lyophilized for stability during shipping
- Bacteriostatic water (3 mL)
About this compound
A synthetic thymosin β4-derived peptide supplied as a 5 mg lyophilized vial for research into actin binding and sequestration, cell migration, angiogenesis, and tissue repair.
- 5 mg lyophilized peptide per vial
- Thymosin β4-derived peptide (TB-500)
- Synthetic peptide, ≥99% purity
- Studied for actin binding, cell migration, and tissue repair
A synthetic thymosin β4-derived peptide supplied as a 10 mg lyophilized vial for research into actin binding and sequestration, cell migration, angiogenesis, and tissue repair.
- 10 mg lyophilized peptide per vial
- Thymosin β4-derived peptide (TB-500)
- Synthetic peptide, ≥99% purity
- Studied for actin binding, cell migration, and tissue repair
Why the lot matters
- Synthesized and tested per lot, never as a production-run average
- Certificate of Analysis published before the lot goes on sale
- Independent lab, contractually separate from manufacturing
What "research use only" means
This product is sold exclusively for in-vitro laboratory research. It is not evaluated by any medicines agency and is not intended for human or animal administration, diagnosis, treatment, or prevention of disease.
Technical data
Technical data
Current lot snapshot
Shipping
Reported use in research
TB-500 is the research designation for a synthetic peptide derived from thymosin β4, a naturally occurring actin-sequestering protein. In preclinical models it is investigated for its capacity to bind and regulate G-actin, a mechanism implicated in cytoskeletal dynamics and cell motility. Researchers study the peptide as a probe for cell migration, endothelial differentiation, and angiogenesis in cultured systems. It is also examined in laboratory wound-healing and tissue-repair paradigms, where actin regulation is thought to influence cellular recruitment. Further investigations explore its interactions with pathways governing inflammation and extracellular-matrix remodeling. All such work is conducted strictly within controlled laboratory settings.
Reported findings
Research reports that thymosin β4-derived peptides promote endothelial cell migration and tube formation in cultured assays. In animal research models of dermal and corneal injury, studies describe accelerated closure and increased vascularization associated with peptide exposure. Preclinical cardiac-injury investigations have reported changes in cell survival and myocyte organization following administration in rodent models. Additional reports note modulation of inflammatory markers and collagen deposition during tissue-repair studies. These observations remain confined to experimental research contexts and have not been established for any clinical application.
Handling & safety
The safety profile of TB-500 has not been completely characterized and its effects in humans are unknown. It should be handled only by qualified personnel using appropriate laboratory protective equipment and standard handling procedures. This material is supplied strictly for in-vitro and preclinical research and is not for human or veterinary use. Reconstituted or dry material should be kept away from unauthorized access and disposed of in accordance with institutional guidelines.
Reconstitution
Recommended ratio
- 1 mL of bacteriostatic water per 10 mg vial
- Equivalent to 10 mg/mL (i.e. 1 mg per 10 units on a 100 U insulin syringe)
- Remove the plastic flip-off lid from the vial.
- Disinfect the rubber stoppers with alcohol wipes.
- Inject the diluent slowly down the inner wall of the vial to avoid foaming.
- Gently swirl the vial (never shake). Let it dissolve for about 10 minutes.
Storage
Unopened / before reconstitution
- Store at a stable temperature.
- Stable for 24 months.
- For long-term storage (2+ years), store at -20 °C.
Reconstituted solution
- Must be kept refrigerated.
- Avoid exposure to light and excessive heat.
3RD-PARTY LAB
| Parameter | Method | Result | Status |
|---|---|---|---|
| Identity confirmation | Mass spectrometry | Consistent with - | PASS |
| Purity | HPLC (area %) | 99.6% | PASS |
| Net peptide content | Gravimetric | 5.00 mg | PASS |
| Appearance | Visual | White to off-white lyophilized powder | PASS |
| Residual solvents | GC headspace | Within limits | PASS |
| Microbial screening | Sterility panel | No growth detected | PASS |
3RD-PARTY LAB
| Parameter | Method | Result | Status |
|---|---|---|---|
| Identity confirmation | Mass spectrometry | Consistent with - | PASS |
| Purity | HPLC (area %) | 99.7% | PASS |
| Net peptide content | Gravimetric | 5.00 mg | PASS |
| Appearance | Visual | White to off-white lyophilized powder | PASS |
| Residual solvents | GC headspace | Within limits | PASS |
| Microbial screening | Sterility panel | No growth detected | PASS |
3RD-PARTY LAB
| Parameter | Method | Result | Status |
|---|---|---|---|
| Identity confirmation | Mass spectrometry | Consistent with - | PASS |
| Purity | HPLC (area %) | 99.4% | PASS |
| Net peptide content | Gravimetric | 5.00 mg | PASS |
| Appearance | Visual | White to off-white lyophilized powder | PASS |
| Residual solvents | GC headspace | Within limits | PASS |
| Microbial screening | Sterility panel | No growth detected | PASS |
3RD-PARTY LAB
| Parameter | Method | Result | Status |
|---|---|---|---|
| Identity confirmation | Mass spectrometry | Consistent with - | PASS |
| Purity | HPLC (area %) | 99.4% | PASS |
| Net peptide content | Gravimetric | 10.02 mg | PASS |
| Appearance | Visual | White to off-white lyophilized powder | PASS |
| Residual solvents | GC headspace | Within limits | PASS |
| Microbial screening | Sterility panel | No growth detected | PASS |
3RD-PARTY LAB
| Parameter | Method | Result | Status |
|---|---|---|---|
| Identity confirmation | Mass spectrometry | Consistent with - | PASS |
| Purity | HPLC (area %) | 99.5% | PASS |
| Net peptide content | Gravimetric | 10.01 mg | PASS |
| Appearance | Visual | White to off-white lyophilized powder | PASS |
| Residual solvents | GC headspace | Within limits | PASS |
| Microbial screening | Sterility panel | No growth detected | PASS |
3RD-PARTY LAB
| Parameter | Method | Result | Status |
|---|---|---|---|
| Identity confirmation | Mass spectrometry | Consistent with - | PASS |
| Purity | HPLC (area %) | 99.6% | PASS |
| Net peptide content | Gravimetric | 9.98 mg | PASS |
| Appearance | Visual | White to off-white lyophilized powder | PASS |
| Residual solvents | GC headspace | Within limits | PASS |
| Microbial screening | Sterility panel | No growth detected | PASS |
| Lot | Filled | Purity | Report | Status | |
|---|---|---|---|---|---|
| VL-2930-A | Jul 2026 | 99.6% | TR-88664 | Active | |
| VL-2949-B | May 2026 | 99.7% | TR-88749 | Sold out | |
| VL-2892-C | Mar 2026 | 99.4% | TR-88722 | Sold out |
| Lot | Filled | Purity | Report | Status | |
|---|---|---|---|---|---|
| VL-2884-A | Jul 2026 | 99.4% | TR-88234 | Active | |
| VL-2903-B | May 2026 | 99.5% | TR-88167 | Sold out | |
| VL-2922-C | Mar 2026 | 99.6% | TR-88368 | Sold out |
